Biospecimen and Pathology Core

生物样本和病理学核心

• 批准号: 10473658
• 负责人: CARL D MORRISON
• 金额: $ 9.86万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-18 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10473658
• 关键词: American; American Society of Clinical Oncology; Archives; Biological Assay; Blood specimen; Clinical; Clinical Research; Clinical Trials; Collection; Coupled; Cytometry; DNA methylation profiling; Data; Diagnostic; Drug or chemical Tissue Distribution; Eligibility Determination; Evaluation; Experimental Designs; Guidelines; Histologic; Histology; Histopathology; Human; Human Resources; Image; Immune; Immunogenomics; Immunohistochemistry; Immunologics; Individual; Informatics; Infrastructure; Ischemia; Malignant neoplasm of ovary; Pathologic; Pathologist; Pathology; Patients; Performance; Phenotype; Preparation; Process; Protocols documentation; Quality Control; Research Personnel; Research Project Grants; Research Support; Sampling; Scanning; Services; Site; Slide; Specimen; Standardization; T cell receptor repertoire sequencing; Testing; Time; Tissue Microarray; Tissues; Training; Translational Research; Tumor Tissue; Tumor-Infiltrating Lymphocytes; automated image analysis; base; biobank; college; data dissemination; digital; digital imaging; exome sequencing; experience; immunological status; informatics infrastructure; interest; laser capture microdissection; next generation sequencing; ovarian neoplasm; sample fixation; tissue resource; tool; transcriptome sequencing; tumor; tumor microenvironment

ABSTRACT The Roswell Park Ovarian Cancer SPORE Biospecimen & Pathology Core (BPC) combines a centralized mechanism for expert tissue handling services and performance of tissue-based assays by highly qualified, experienced personnel with a state-of-the-art integrated informatics infrastructure which provides tools for tracking biospecimen collection, histopathological evaluation, and clinical annotation of samples with linkage to immunogenomic and other translational data generated by the Individual Research Projects proposed in this renewal application. The Core will collect, de-identify, process, bank, and distribute annotated, high-quality tumor and blood samples from patients participating in SPORE-sponsored clinical studies. In addition, the BPC will provide investigators with specialized technical and interpretative histopathology services including expertise in multiplexed immunohistochemistry (IHC) and imaging mass cytometry (IMC), tissue microarray construction, laser capture microdissection, digital imaging, and quantitative pathology review of slides, tumor- infiltrating lymphocytes assessment, tissue QC/QA and preparation for next-gen sequencing-based assays (whole exome seq, RNAseq, TCRseq, MethylSEQ), and oversight on optimal utilization of each biospecimen. The Core will also be instrumental in testing patient biospecimens to determine eligibility for clinical trials and directly add to the bi-directional translational science by a detailed immunological annotation of ovarian tumors.

摘要